LuTectomy : Study of the Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Radionuclide Therapy Prior to Radical Prostatectomy in Men With High-risk Localised Prostate Cancer

Male<br/>OnlyGender Male
Only

RecruitingStatus Recruiting

Radiotherapy<br/>TrialTypeRadiotherapy
Trial

One/TwoPhase One/Two

18+Age Over 18

Prostate<br/>CancersCancer LocationProstate
Cancers

Radiotherapy,Surgical,Treatment | Urinary systemProstate

Trial Overview Read MoreRead more

This trial aims to evaluate a radiation-based treatment in men with prostate cancer who are undergoing surgery for their cancer.
 

This trial is treating patients with PSMA-expressing high-risk localized or locoregional advanced prostate cancer (HRCaP).

This is a radiation therapy and surgical trial.

You may be able to join this trial if:

  • Your cancer has not spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Study of the Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Radionuclide Therapy Prior to Radical Prostatectomy in Men With High-risk Localised Prostate Cancer

Other Non-Commercial Sponsor

Peter MacCallum Cancer Centre

Summary

Eligible patients will receive one or two cycles of 177Lu-PSMA followed by surgery (prostatectomy).

Recruiting Hospitals Read MoreRead more

Peter MacCallum Cancer Centre, Molecular Imaging
Parkville
Dr Annette Hogg
annette.hogg@petermac.org
03 9656 3744

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next